( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 106 10 25
食道癌診療指引 106 105 106-1.2 T1b-3,N0-2 T4,N0-2 T1-4,N3 Tany,Nany,M1 癌症診療指引166
食道癌診療指引共識1-1 ( ) ( : : ) Tis T1a T1b-T3, N0-N2 ( ) ( ) 癌症診療指引167 : 1. Adenocarcinoma; 2. ; 3. <1mm; 4. ; 5.
食道癌診療指引共識2-2 ( ) ( : : ) T4, N0-2 T1-4, N3 T any, N any M1 1. 2. 3. 4. 癌症診療指引168
食道癌診療指引 參考文獻 1. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers Version 2.2017. 2. AJCC Cancer Staging Manual 8th ed. 2017. p185-202. Springer International Publishing, MI:AJCC. 3. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26:4551-4556. 4. Allum WH, Fogarty PJ, Stenning SP, et al. Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. Proc ASCO GI 2008, abstr 9 5. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168. 6. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167. 7. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.lancet Oncol 2005;6:659-668 8. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627. 9. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med 2006;355:11-20. 10. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-432. 11. Gaspar LE, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 2000;88:988-995. 癌症診療指引169
癌症診療指引170 Preoperative Chemoradiation Therapy of Esophageal Cancer PREFERRED REGIMENS Paclitaxel + Carboplatin Paclitaxel 50 1 QW 5 1 Carboplatin 2 AUC 1 QW 5 Cisplatin + Fluoropyrimidine Cisplatin 75-100 1, 29 Q35D 1 2 5-FU 750-1000* 1-4, 29-32 Q35D 1 Cisplatin 15 1-5 Q3W 2 3 5-FU 800 1-5 Q3W 2 Cisplatin 30 1 QW 5 4 Capecitabine 800 PO BID 1-5 QW 5
+ Fluoropyrimidine Oxaliplatin 癌症診療指引171 Oxaliplatin 85 1 Q2W 3(RT) + 3 5 Leucovorin 200 1 Q2W 3(RT) + 3 5-FU 400 1 Q2W 3(RT) + 3 5-FU 800* 1-2 Q2W 3(RT) + 3 Paclitaxel + Carboplatin Oxaliplatin 85 1, 15, 29 For 3 doses 6 Capecitabine 625 PO BID 1-5 QW 5 OTHER REGIMENS Irinotecan + Cisplatin Irinotecan 65 1, 8, 22, 29 1 7 Cisplatin 30 1, 8, 22, 29 1 Paclitaxel + Fluoropyrimidine Paclitaxel 45-50 1 QW 5 8 5-FU 300* 1-5 QW 5
mg/m2 癌症診療指引172 Paclitaxel 45-50 1 QW 5 8 Capecitabine 625-825 PO BID 1-5 QW 5 Perioperative Chemotherapy (Include EGJ) ECF modications Epirubicin 50 1 Q3W 6* 9 Cisplatin 60 1 Q3W 6* Capecitabine 625 PO BID 1-21 Q3W 6* *3(pre-op) + 3(post-op) Epirubicin 50 1 Q3W 6* 9 Oxaliplatin 130 1 Q3W 6* Capecitabine 625 PO BID 1-21 Q3W 6* *3(pre-op) + 3(post-op) Fluorouracil and cisplatin Cisplatin 75-80 1 Q4W 6# 10 5-FU 800* 1-5 Q4W 6# # 2~3 (pre-op) + 3~4 (post-op)
+ Fluoropyrimidine Oxaliplatin 癌症診療指引173 Oxaliplatin 85 1 Q2W 6# 21 Leucovorin 400 1 Q2W 6# 5-FU 400 1 Q2W 6# 5-FU 1200* 1-2 Q2W 6# # 3 (pre-op) + 3 (post-op) Oxaliplatin 85 1 Q2W 6# 22 Leucovorin 200 1 Q2W 6# 5-FU 2600* 1 Q2W 6# # 3 (pre-op) + 3 (post-op) Oxaliplatin 130 1 Q3W 6# 23 Capecitabine 1000 PO BID 1-14 Q3W 6# # 3 (pre-op) + 3 (post-op)
Chemoradiation (Non-Surgical) Difinitive 癌症診療指引174 PREFERRED REGIMENS Cisplatin + Fluoropyrimidine Cisplatin 75-100 1 Q4W 2~4# 11 5-FU 750-1000* 1-4 Q4W 2~4# # 2 (RT) + 2 Cisplatin 30 1 QW 5 4 Capecitabine 800 PO BID 1-5 QW 5 Oxaliplatin + Fluoropyrimidine Oxaliplatin 85 1 Q2W 6# 5 Leucovorin 400 1 Q2W 6# 5-FU 400 1 Q2W 6# 5-FU 800* 1-2 Q2W 6# # 3 (RT) + 3 (post-rt) Oxaliplatin 85 1, 15, 29 For 3 doses 6 Capecitabine 625 PO BID 1-5 QW 5
+ Carboplatin Paclitaxel 癌症診療指引175 Paclitaxel 50 1 QW 5 1 Carboplatin 2 AUC 1 QW 5 OTHER REGIMENS Taxane + Cisplatin Paclitaxel 60 1, 8, 15, 22 1 12 Cisplatin 75 1 1 Docetaxel 60 1, 22 1 13 Cisplatin 60-80 1, 22 1 Docetaxel 20-30 1 QW 5 14 Cisplatin 20-30 1 QW 5 Irinotecan + Cisplatin Irinotecan 65 1, 8, 22, 29 1 7 Cisplatin 30 1, 8, 22, 29 1
+ Fluoropyrimidine Paclitaxel 癌症診療指引176 Paclitaxel 45-50 1 QW 5 8 5-FU 300* 1-5 QW 5 Paclitaxel 45-50 1 QW 5 8 Capecitabine 625-825 PO BID 1-5 QW 5 Postoperative Chemoradiation (Including EGJ) 5-FU (bolus) + Leucovorin Lecucovorin 20 1-5 Q4W 1 st, 3 rd, 4 th # 15 5-FU 425 1-5 Q4W 1 st, 3 rd, 4 th # Lecucovorin 20 1-4, 31-33 Q5W 2 nd (with RT) 5-FU 400 1-4, 31-33 Q5W 2 nd (with RT) # Cycle 1 st (pre-rt), and cycle 3 rd, 4 th (posr-rt)
+ Leucovorin modifications 5-FU 癌症診療指引177 1 cycle before + 2 cycle after chemoradiation Capecitabine 750-1000 PO BID 1-14 Q4W 1 + 2 16 Leucovorin 400 1, 15 or 1,2,15,16 Q4W 1 + 2 16 5-FU 400 1, 15 or 1,2,15,16 Q4W 1 + 2 5-FU 600 CIVD 22 H 1, 2, 15, 16 Q4W 1 + 2 With radiation 5-FU 200-250* 1-5 or 1-7 QW 5 with RT 18 Capecitabine 625-825 PO BID 1-5 or 1-7 QW 5 with RT 19 Postoperative Chemotherapy Oxaliplatin + Capecitabine Oxaliplain 130 1 Q3W 20 Capecitabine 1000 PO BID 1-14 Q3W
癌症診療指引178 1. Van Hagen P, Hulshof MC, van Lanschot, J.J, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 2012;366:2074-2084. 2. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy,and surgery compared with surgery alone for esophagealcancer: CALGB 9781. J Clin Oncol 2008;26:1086-1092. 3. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160-1168. 4. Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol 2007;37:829-835. 5. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.lancet Oncol 2014;15:305-314. 6. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 2009;27:193-200. 7. Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. J Clin Oncol 2009;27 (Suppl 15):Abstract e15619. 8. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24:3953-3958. 9. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with
oesophagogastric cancer receiving ECF.Br J Cancer 2005;92:1976-1983. advanced 癌症診療指引179 10. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721. 11. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: highdose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-1174. 12. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophagealcarcinoma. Cancer 003;98:2177-2183. 13. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus 2010;23:253-259. 14. Day FL, Leong T, Ngan S, et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer 2011;104:265-271. 15. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. 16. Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 2007;69:1424-1428. 17. Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007;25:3732-3738. 18. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-Fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-Fluorouracil: a multicenter study of the trans-tasman radiation oncology group. Int J Radiat Oncol Biol Phys 2011;79:690-695. 19. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol 2006;12:603-607. 20. NCCN [ESOPH-F] Version 3, 2017.
therapy for metastatic or locally advanced cancer Systemic 癌症診療指引180 (where local therapy is not indicated) FIRST-LINE THERAPY Trastuzumab (with chemotherapy) Trastuzumab 8 6 mg/kg 1 Q3W 1 Trastuzumab (with chemotherapy) Trastuzumab 6 4 mg/kg 1 Q2W 1 PREFERRED REGIMENS Fluoropyrimidine + Cisplatin Cisplatin 75-100 1 Q4W 9 5-FU 750-1000* 1-4 Q4W Cisplatin 50 1 Q2W 10, 11 Leucovorin 200 1 Q2W 5-FU 2000* 1 Q2W
mg/m2 癌症診療指引181 Cisplatin 80 1 Q3W 12 Capecitabine 1000 PO BID 1-4 Q3W Fluoropyrimidine + Oxaliplatin Oxaliplatin 85 1 Q2W 13 Leucovorin 400 1 Q2W 5-FU 400 1 Q2W 5-FU 1200* 1-2 Q2W Oxaliplatin 85 1 Q2W 10 Leucovorin 200 1 Q2W 5-FU 2600* 1 Q2W Oxaliplatin 130 1 Q3W 14 Capecitabine 1000 PO BID 1-14 Q3W
DCF 癌症診療指引182 Docetaxel 75 1 Q3W 2 Cisplatin 75 1 Q3W 5-FU 750* 1-5 Q3W DCF modifications Docetaxel 40 1 Q2W 3 Leucovorin 40 1 Q2W 5-FU 400 1 Q2W 5-FU 1000* 1-2 Q2W Cisplatin 75 3 Q2W Docetaxel 50 1 Q2W 4 Oxaliplatin 85 1 Q2W 5-FU 1200* 1-2 Q2W
REGIMENS OTHER 癌症診療指引183 Paclitaxel + Cisplatin/Carboplatin Paclitaxel 135-200 1 Q3W 15 Cisplatin 75 2 Q3W Paclitaxel 90 1 Q2W 16 Cisplatin 50 1 Q2W Paclitaxel 200 1 Q3W 17 Carboplatin 5 AUC 1 Q3W Docetaxel + Cisplatin Docetaxel 75-85 1 Q3W 18, 19 Cisplatin 70-75 1 Q3W Fluoropyrimidine Leucovorin 400 1 Q2W 11 5-FU 400 1 Q2W 5-FU 1200* 1-2 Q2W
mg/m2 癌症診療指引184 5-FU 800* 1-5 Q4W 21 Capecitabine 1000-1250 PO BID 1-14 Q3W 22 Taxane Docetaxel 75-100 1 Q3W 23, 24 Paclitaxel 135-250 1 Q3W 25 Paclitaxel 80 1, 8, 15, 22 Q4W 26
+ 5-FU Irinotecan 癌症診療指引185 Irinotecan 180 1 Q2W 7 Leucovorin 400 1 Q2W 5-FU 400 1 Q2W 5-FU 1200* 1-2 Q2W Irinotecan 80 1 QW 8 Leucovorin 500 1 QW 5-FU 2000* 1 QW ECF modifications Epirubicin 50 1 Q3W 6 Cisplatin 60 1 Q3W Capecitabine 625 PO BID 1-21 Q3W Epirubicin 50 1 Q3W 6 Oxaliplatin 130 1 Q3W Capecitabine 625 PO BID 1-21 Q3W
THERAPY SECOND-LINE 癌症診療指引186 PREFERRED REGIMENS Taxane Docetaxel 75-100 1 Q3W 23, 24 Paclitaxel 135-250 1 Q3W 25 Paclitaxel 80 1, 8, 15, 22 Q4W 26 Paclitaxel 80 1, 8, 15 Q4W 27 Irinotecan Irinotecan 250-350 1 Q3W 29 Irinotecan 150-180 1 Q2W 27, 28
+ Fluoropyrimidine Irinotecan 癌症診療指引187 Irinotecan 180 1 Q2W 7 Leucovorin 400 1 Q2W 5-FU 400 1 Q2W 5-FU 1200* 1-2 Q2W OTHER REGIMENS Irinotecan + Cisplatin Irinotecan 65 1, 8 Q3W 13, 29 Cisplatin 25-30 1, 8 Q3W Pembrolizumab (MSI-H/dMMR tumors) Pembrolizumab 200 mg 1 Q3W 30 1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010;376:687-697. 2. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin
2006;24:4991-4997. Oncol 癌症診療指引188 3. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-874. 4. Shankaran V, Mulcahy MF, Hochster HS, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. Gastrointestinal Cancers Symposium 2009:Abstract 47. 5. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46. 6. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. J Clin Oncol 2014;32:3520-3526 7. Wolff K, Wein A, Reulbach U, et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs 2009;20:165-173. 8. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-1673. 9. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442. 10. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol
2004;22:4319-4328. 癌症診療指引189 11. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673. 12. Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. J Clin Oncol 2010;28 (Suppl 15):Abstract 4006. 13. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012;48:518-526. 14. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316-323. 15. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998;78:511-514. 16. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:37-41. 17. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-5667. 18. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 2010;66:31-36. 19. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59. 20. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004;15:1344-1347. 21. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med
2007;24:407-412. Oncol 癌症診療指引190 22. Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78-86. 23. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-1091. 24. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898-902. 25. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 Trial. J Clin Oncol 2013;31:4438-4444. 26. Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mfolfiri) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol 2013;71:481-488. 27. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314. 28. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-814. 29. Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004;18:22-25. 30. Product Information: KEYTRUDA(R) intravenous injection, pembrolizumab intravenous injection. Merck Sharp & Dohme Corp (per FDA), Whitehouse Station, NJ, 2017.
食道癌放射治療共識 1. 2. 3. / 1. (a) / 50Gy(50~50.4Gy) * (b) 48Gy(45~50.4Gy) (c) 27 (25~30 ) ( ) 1. (a) 50Gy(50~50.4Gy) * (b) 48Gy(45~50.4Gy) (c) 27 (25~30 ) * 60~66 Gy 60 Gy 1. (a) 48Gy(45~50.4Gy) (b) 48Gy(45~50.4Gy) (c) 27 (25~30 ) 2. (a) 41.4Gy (b) 41.4Gy (c) 23 癌症診療指引191
食道癌放射治療共識 : 1. International Commission on Radiation Units and Measurements. ICRU Report No 50: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: ICRU Publications 1993. 2. Cooper JS, GUO MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial RTOG 85-01. Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627. 3. International Commission on Radiation Units and Measurements. ICRU Report No 62: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: ICRU Publications 1999. 4. Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Raiother Oncol 1999; 51: 21-26. 5. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 Radiation Therapy Oncology Group 94-05 phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174. 6. Willett CG, et al. Principles and Practice of Radiation Oncology. 5th edition: Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1131-1153. 7. P. van Hagen, M.C.C.M. Hulshof, J.J.B. van Lanschot, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 2012; 366:2074-2084. 8. NCCN clinical practice guidelines in oncology for esophageal and esophagogastric junction cancers. Version 2, 2017. 癌症診療指引192